Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Rating of “Hold” by Brokerages

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have received an average rating of “Hold” from the five brokerages that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $7.00.

Several equities research analysts recently issued reports on MIST shares. TD Cowen cut shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 1st. HC Wainwright raised shares of Milestone Pharmaceuticals to a “buy” rating and set a $5.00 price objective on the stock in a report on Thursday, June 5th. Cowen cut shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 1st. Finally, TD Securities lowered shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 1st.

Milestone Pharmaceuticals Price Performance

MIST stock opened at $1.65 on Friday. Milestone Pharmaceuticals has a 12 month low of $0.63 and a 12 month high of $2.75. The company has a 50-day moving average price of $1.67 and a 200 day moving average price of $1.68. The stock has a market cap of $88.21 million, a PE ratio of -2.12 and a beta of 0.96. The company has a current ratio of 4.67, a quick ratio of 4.67 and a debt-to-equity ratio of 4.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.12). Equities research analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Institutional Trading of Milestone Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Propel Bio Management LLC bought a new stake in shares of Milestone Pharmaceuticals during the first quarter valued at about $1,161,000. Toronto Dominion Bank acquired a new stake in shares of Milestone Pharmaceuticals during the 4th quarter valued at about $1,770,000. Boxer Capital Management LLC acquired a new stake in Milestone Pharmaceuticals in the 4th quarter worth approximately $729,000. Walleye Capital LLC acquired a new position in shares of Milestone Pharmaceuticals during the first quarter worth approximately $74,000. Finally, Virtu Financial LLC acquired a new position in shares of Milestone Pharmaceuticals in the fourth quarter valued at $170,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.